ConductScience.org, home

Paper11057778

'Hot flush', an unpleasant symptom accompanying antiandrogen therapy of prostatic cancer and its treatment by cyproterone acetate.

Cervenákov I and 4 others. Int Urol Nephrol, 2000. Cited by 15 papers, by iCite.

Cite this record

ConductScience Library. 'Hot flush', an unpleasant symptom accompanying antiandrogen therapy of prostatic cancer and its treatment by cyproterone acetate. Papers, record 11057778. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/11057778

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
'Hot flush', an unpleasant symptom accompanying antiandrogen therapy of prostatic cancer and its treatment by cyproterone acetate.
PubMed
Journal
Int Urol Nephrol
PubMed
Year
2000
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
15
iCite
Relative citation ratio, by iCite
0.49
iCite
Revised in PubMed
2026-10-16
PubMed

Authors5

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Cervenákov II
2Kopecný MM
3Jancár MM
4Chovan DD
5Mal'a MM

Source PubMed

Download CSV of authors

Topics11

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Androgen AntagonistsMajor topic
Cyproterone AcetateMajor topic
Hot FlashesMajor topic
OrchiectomyMajor topic
ProstatectomyMajor topic
Prostatic NeoplasmsMajor topic
Aged
Aged, 80 and over
Humans
Male
Middle Aged

Source PubMed

Download CSV of topics

References11

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
17688656Luteinizing hormone-releasing hormone agonists in prostate cancer. Elimination of flare reaction by pretreatment with cyproterone acetate and low-dose diethylstilbestrol.Cancer1993https://conductscience.org/library/papers/7688656PubMed
28201642A prospective comparison of treatments for symptomatic hot flushes following endocrine therapy for carcinoma of the prostate.J Urol1994https://conductscience.org/library/papers/8201642PubMed
38821690A prospective, randomised study to compare goserelin acetate (Zoladex) versus cyproterone acetate (Cyprostat) versus a combination of the two in the treatment of metastatic prostatic carcinoma.Eur Urol1996https://conductscience.org/library/papers/8821690PubMed
48536770Advances and trends in hormonal therapy for advanced prostate cancer.Eur Urol1995https://conductscience.org/library/papers/8536770PubMed
58197933Androcur 50 in the treatment of prostatic carcinoma. Belgian multicentric study with the participation of 30 urologists.Acta Urol Belg1994https://conductscience.org/library/papers/8197933PubMed
68308973Transdermal clonidine for ameliorating post-orchiectomy hot flashes.J Urol1994https://conductscience.org/library/papers/8308973PubMed
77528960[Hot flashes after orchiectomy in treatment of prostate cancer-- a serious side effect].Z Gerontol1994https://conductscience.org/library/papers/7528960PubMed
87919640Cyproterone. A review of its pharmacology and therapeutic efficacy in prostate cancer.Drugs Aging1994https://conductscience.org/library/papers/7919640PubMed
948206Physiologic basis for hormonal theapy in carcinoma of the prostate.Urol Clin North Am1975https://conductscience.org/library/papers/48206PubMed
109549167[Therapy of vasomotor syndrome in the treatment of advanced prostatic cancer: apropos of 37 cases].Arch Ital Urol Androl1998https://conductscience.org/library/papers/9549167PubMed
119519356
Maximum androgen blockade using LHRH agonist buserelin in combination with short-term (two weeks) or long-term (continuous) cyproterone acetate is not superior to standard androgen deprivation in the treatment of advanced prostate cancer. Final analysis of EORTC GU Group Trial 30843. European Organization for Research and Treatment of Cancer (EROTC) Genito-Urinary Tract Cancer Cooperative Group.
Eur Urol1998https://conductscience.org/library/papers/9519356PubMed

Download CSV of references

Cited by2

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 15 citations.

PMIDTitleJournalYearIn PapersSource
16985883Adverse events associated with hormonal therapy for prostate cancer.Rev Urol2005https://conductscience.org/library/papers/16985883PubMed
15869726Preventing and treating the complications of hormone therapy.Curr Urol Rep2005https://conductscience.org/library/papers/15869726PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/11057778

GET https://conductscience.org/api/papers/v1/11057778/authors